Arkayli Biopharma, Inc.
Katie MacFarlane, PharmD, is a seasoned pharmaceutical executive with extensive experience in the industry. As the Founder and President of SmartPharma LLC since October 2007, Katie has focused on the commercialization and development of pharmaceutical products, providing strategic support to various companies. Current roles include serving as a Board Member at PharmAust and Mayne Pharma, along with contributing to the Science and Technology Committee. Katie also leads commercial efforts at Arkayli Biopharma, Inc., and has held significant positions at reputable organizations such as Agile Therapeutics, Xintria Pharmaceuticals, and Warner Chilcott. Katie's educational foundation includes a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from Purdue University.
This person is not in any teams
This person is not in any offices
Arkayli Biopharma, Inc.
Our mission is to develop novel medications with precision drug delivery systems to enhance efficacy and maximize safety of treatments for children and adults with vascular anomalies. Our lead product candidate, ARK001, has the potential to be the first FDA-approved non-systemic topical (applied to the skin) treatment for infantile hemangioma (IH). ARK001 has the potential to change the approach to care for IH, allowing pediatricians and dermatologists to treat before the IH requires systemic therapy.